Overview

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

Status:
Completed
Trial end date:
2008-01-30
Target enrollment:
Participant gender:
Summary
Randomized, double-blinded study that will evaluate the tolerability, safety, and flow rates of different solutions subcutaneously (SC) infused and preceded by human recombinant hyaluronidase (hylenex) 150 units. In Stage 1, the comparison will be Normal Saline (NS) solution to Lactated Ringer's (LR) solution. Each subject will receive 500 milliliters (mL) of solution, consisting of NS in one thigh and LR in the other thigh. Immediately prior to the infusions, each thigh will have 150 units of hylenex. In Stage 2, the comparison will be NS solution and buffered NS solution.
Phase:
Phase 4
Details
Lead Sponsor:
Halozyme Therapeutics
Collaborator:
Baxter Healthcare Corporation